Can-Fite's CF101 meets in Phase IIb RA trial

Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF) said twice-daily oral CF101 met the primary endpoint of improving ACR20 response rate at week 12 vs. placebo in a Phase IIb trial to treat rheumatoid arthritis (49% vs. 25%, p=0.035). There was no reported evidence of immunosuppression. The double-blind, international trial enrolled 79 active RA patients with elevated baseline expression levels of adenosine A3 receptor (ADORA3) in peripheral blood mononuclear cells (PBMCs). Data are slated to be presented at the Autoimmunity meeting in March. Can-Fite could not be reached for next steps with CF101, an ADORA3 agonist, in the indication.

CF101 is also in Phase III testing to treat dry eye syndrome, Phase II/III testing for psoriasis and Phase II testing for glaucoma. In November, Can-Fite signed confidentiality agreements with 10 companies for negotiations to commercialize CF101 to treat autoimmune diseases. OphthaliX Inc. (OTCBB:OPLI) has exclusive, worldwide rights to CF101 from Can-Fite for ophthalmic indications. ...